Vaxcyte (PCVX) Stock Soars As VAX-31 Data Smash Expectations

Vaxcyte Inc. (PCVX) stock rose 8.72% on October 9, 2026, following positive data from its VAX-31 vaccine trial, which met all primary endpoints. The stock saw a significant surge after the OPUS-1 trial results, with analysts setting price targets up to $163. Vaxcyte reported strong financials but remains pre-revenue with ongoing R&D expenses.

Original reporting
Published Oct 9, 2026, 4:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 5:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vaxcyte (PCVX) Stock Soars As VAX-31 Data Smash Expectations — source image
Decision brief

The 30-second read

$PCVXBullishHigh
01

Why it matters

Analyst upgrades and target hikes reflect de‑risking; momentum may sustain short‑term but long‑term upside depends on BLA filing and financing.

02

Market read

The trial data creates a catalyst for PCVX and may lift peer biotech stocks.

03

What to watch

Dilution from upcoming $1B raise and cash burn could limit upside if momentum fades.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Vaxcyte (PCVX) announced positive Phase 3 data for its VAX-31 pneumococcal vaccine, triggering a sharp stock move.

Company-level read

Ticker impact

$PCVXBullishHigh confidence
Context

Positive Phase 3 OPUS-1 trial data for VAX-31 vaccine drove an 8%+ intraday surge and analyst target upgrades.

Expected impact

upward bias as momentum continues, with potential pull‑back near $70 support.

Evidence & confidence

Analyst upgrades and $146‑$163 target range suggest further upside; price may test $120‑$150 zone if rally sustains.

Market effects

Biotech sector may see broader rally on positive late‑stage trial news.

U.S. biotech stocks gain as investors reprice clinical risk.

Positive vaccine data could influence global pneumococcal market outlook.

Counterpoint

If the rally is driven by short‑cover, a pull‑back to $60‑$65 is possible.

Key entities

  • Vaxcyte Inc.

    Clinical‑stage biotech developing VAX-31 vaccine.

  • Jefferies

    Raised price target to $146 on trial success.

Related articles

HighAI 9/10

Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals

Vaxcyte's VAX-31 pneumococcal vaccine met all primary endpoints in the phase 3 OPUS-1 trial, showing noninferior immune responses to existing vaccines and superior responses for unique serotypes. The trial enrolled 4,047 adults and demonstrated safety with mostly mild reactions. Vaxcyte plans to submit a BLA in 2028, with additional data expected in 2027. The vaccine aims to cover 86.7% of adult nonbacteremic pneumonia and 93.9% of adult IPD, addressing a significant healthcare burden.

$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety P

$PCVXHighAI 8/10

Vaxcyte’s vaccine candidate met every main goal in a trial of 4,047 adults. More trial results are expected in 2027.

Vaxcyte's VAX-31 vaccine met all primary endpoints in a Phase 3 trial of 4,047 adults, showing safety and efficacy. The company plans to report more trial results in 2027 and submit a BLA in 2028. VAX-31 is designed to prevent pneumococcal disease. Vaxcyte also announced progress in its VAX-A1 vaccine candidate for Group A Streptococcus.